WCN26-2797 Impact of Polypharmacy on the Efficacy and Safety of SGLT2 Inhibitors in Patients with Chronic Kidney Disease: Insights from the CREDENCE trial

Read full text Summarise with VIRAT
Authors: Emily K. Yeung, Amanda N. Siriwardana, Luke Buizen, Arthur H. C. Tang, Lauren Heath, Min Jun, Sydney Chi-Wai TANG, Sradha S. Kotwal, Clare Arnott, Adeera Levin, Meg Jardine, Kenneth W. Mahaffey
+3 more Vlado Perkovic, Hiddo J.L. Heerspink, Brendon Lange Neuen
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The burden of polypharmacy in patients with chronic kidney disease (CKD) is substantial and exceeds most other chronic diseases. Clinicians and patients are often reluctant to add new medications to already complex treatment regimens, partly due to concerns about diminishing efficacy and increased adverse effects, contributing to underuse of guideline directed medical therapies. We assessed whether the efficacy and safety of canagliflozin is modified by polypharmacy status in patients with type 2 diabetes and CKD.

Fields of Study & Subjects

Diabetes Treatment and Management Chronic Kidney Disease and Diabetes Pharmaceutical Practices and Patient Outcomes

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104597–104597
Publication date
25 March 2026
Language
EN